Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
Abraxis Pharmaceutical Products (Nasdaq: ABBI) today announced it has received approval from the Food and Drug Administration for two products, a lyophilized version and a liquid version of Fludarabine phosphate. Fludarabine is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.
Abraxis Pharmaceutical manufactures and markets one of the most comprehensive injectable portfolios of products to the U.S. hospital-based market. The current injectable portfolio is comprised of anti-infectives, critical care, oncology and anesthetic/analgesic products totaling over 400 dosage forms
Abraxis Pharmaceutical manufactures and markets one of the most comprehensive injectable portfolios of products to the U.S. hospital-based market. The current injectable portfolio is comprised of anti-infectives, critical care, oncology and anesthetic/analgesic products totaling over 400 dosage forms
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
- Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
